Monday, March 3, 2025 – Obesity rates are set to skyrocket, with one in six children and adolescents worldwide forecast to be obese by 2050, according to a new study. But with significant increases predicted within the next five years, the researchers stress urgent action now could turn the tide on the public health crisis.
Monday, March 3, 2025 – Researchers investigating the role of the protein CD44 in obesity and metabolic health found that CD44-deficient mice stayed lean even on a high-fat diet, while the control mice developed obesity. A new study published in The American Journal of Pathology details the unexpected pivotal role of CD44, highlighting how it regulates fat cell formation and metabolic health.
Monday, March 3, 2025 – New to Pink Sheet? · US FDA Employs Familiar Strategy In Ending Novo's Wegovy, Ozempic Shortage · US FDA Takes Lilly's Mounjaro, Zepbound Off Shortage ...
Monday, March 3, 2025 – The Zepbound line extension and price reductions are aimed to appeal to self-pay customers. (Shutterstock). Eli Lilly is introducing reduced price ...
Monday, March 3, 2025 – Are GLP-1 therapies truly safe for long-term cardiovascular health? Dr Pandey unpacks key gaps in current research, real-world data, ...
Monday, March 3, 2025 – A local surgeon finds GLP 1 helps his patients who need knee and hip replacements.
Monday, March 3, 2025 – ... of the shortage for popular GLP-1 weight loss drugs Ozempic and Wegovy, the Alliance for Safe Biologic ...
Monday, March 3, 2025 – In a partnership marking AbbVie's entrance into the weight management field, the US pharma major has signed a licensing deal with Denmark's Gubra ...
Monday, March 3, 2025 – ... Zepbound, which are based on the GLP-1 hormone. This differentiation could provide AbbVie with a unique foothold in the competitive landscape. On ...
Monday, March 3, 2025 – ... GLP-1.” “Our population is getting healthier. You don't have to be a full-fledged diabetic with heart failure, or risk, to benefit from GLP-1.